[go: up one dir, main page]

HRP20190057T1 - Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih - Google Patents

Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih

Info

Publication number
HRP20190057T1
HRP20190057T1 HRP20190057TT HRP20190057T HRP20190057T1 HR P20190057 T1 HRP20190057 T1 HR P20190057T1 HR P20190057T T HRP20190057T T HR P20190057TT HR P20190057 T HRP20190057 T HR P20190057T HR P20190057 T1 HRP20190057 T1 HR P20190057T1
Authority
HR
Croatia
Prior art keywords
quetiapin
production
fatty acid
same
fatty
Prior art date
Application number
HRP20190057TT
Other languages
English (en)
Inventor
Travis Mickle
Sven Guenther
Sanjib Bera
Original Assignee
Kempharm, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm, Inc. filed Critical Kempharm, Inc.
Publication of HRP20190057T1 publication Critical patent/HRP20190057T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20190057TT 2010-03-11 2011-03-09 Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih HRP20190057T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31297710P 2010-03-11 2010-03-11
PCT/US2011/027658 WO2011112657A1 (en) 2010-03-11 2011-03-09 Fatty acid conjugates of quetiapine, process for making and using the same
EP11753975.9A EP2544536B1 (en) 2010-03-11 2011-03-09 Fatty acid conjugates of quetiapine, process for making and using the same

Publications (1)

Publication Number Publication Date
HRP20190057T1 true HRP20190057T1 (hr) 2019-03-22

Family

ID=44560214

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190057TT HRP20190057T1 (hr) 2010-03-11 2011-03-09 Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih

Country Status (15)

Country Link
US (7) US20110223207A1 (hr)
EP (2) EP3476218A1 (hr)
CY (1) CY1121106T1 (hr)
DK (1) DK2544536T3 (hr)
ES (1) ES2705233T3 (hr)
HR (1) HRP20190057T1 (hr)
HU (1) HUE042945T2 (hr)
LT (1) LT2544536T (hr)
PL (1) PL2544536T3 (hr)
PT (1) PT2544536T (hr)
RS (1) RS58335B1 (hr)
SI (1) SI2544536T1 (hr)
SM (1) SMT201900079T1 (hr)
TR (1) TR201900067T4 (hr)
WO (1) WO2011112657A1 (hr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104607053B (zh) * 2009-06-26 2017-04-12 Bl 科技公司 非编织、织物增强的中空纤维膜
EP2519101B1 (en) 2009-12-31 2015-08-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
HUE061170T2 (hu) 2010-09-15 2023-05-28 Bl Technologies Inc Eljárás fonalerõsített üreges rost membránok elõállítására oldható mag körül
US20140161748A1 (en) * 2011-05-13 2014-06-12 University Of Manitoba Methods for treating sun-exposed skin
US9321014B2 (en) * 2011-12-16 2016-04-26 Bl Technologies, Inc. Hollow fiber membrane with compatible reinforcements
US9643129B2 (en) 2011-12-22 2017-05-09 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
US9022229B2 (en) 2012-03-09 2015-05-05 General Electric Company Composite membrane with compatible support filaments
US8999454B2 (en) 2012-03-22 2015-04-07 General Electric Company Device and process for producing a reinforced hollow fibre membrane
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ.ベー. アリピプラゾールハプテンに対する抗体及びその使用
PL3333195T3 (pl) 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
CA2882557C (en) * 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of quetiapine for use in immunoassays
CA2882597C (en) 2012-08-21 2020-04-14 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine haptens and use thereof
EP2888263B1 (en) 2012-08-21 2018-05-09 Janssen Pharmaceutica NV Haptens of risperidone and paliperidone
JP2015527365A (ja) 2012-08-21 2015-09-17 オルソ−クリニカル ダイアグノスティクス,インコーポレイティド パリペリドンに対する抗体及びその使用
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
ES2701062T3 (es) 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
PL3354751T3 (pl) 2012-08-21 2020-03-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
ES2733963T3 (es) 2012-08-21 2019-12-03 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de olanzapina y uso de los mismos
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
JP6286429B2 (ja) 2012-08-21 2018-02-28 ヤンセン ファーマシューティカ エヌ.ベー. パリペリドンのハプテン
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
PT2888234T (pt) 2012-08-21 2018-02-22 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
US9227362B2 (en) 2012-08-23 2016-01-05 General Electric Company Braid welding
WO2014057439A2 (en) * 2012-10-13 2014-04-17 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
KR20150133172A (ko) * 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
CN108368180B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途
MA44056A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps anti-rispéridone et leur utilisation
US11066500B2 (en) * 2016-07-27 2021-07-20 Dow Global Technologies Llc Crosslinkable surfactants
WO2018045094A1 (en) * 2016-08-31 2018-03-08 The Board Of Trustees Of The Leland Stanford Junior University Ladderane lipid compounds and liposomes and methods of preparing and using the same
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR20250069077A (ko) * 2023-11-10 2025-05-19 아주대학교산학협력단 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064138A (en) * 1975-11-12 1977-12-20 General Mills, Inc. Amino acid derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
ES2120477T3 (es) 1992-01-21 1998-11-01 Macrochem Corp Administracion iontoforetica de medicamentos perfeccionada.
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US6623752B1 (en) * 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
CA2458968A1 (en) * 2001-08-31 2003-03-13 The Rockefeller University Method for classification of anti-psychotic drugs
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
ES2379544T3 (es) * 2001-09-27 2012-04-27 Ramot At Tel Aviv University Ltd. Conjugado de perfenazina y GABA y usos del mismo
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
WO2005002587A1 (en) 2003-07-02 2005-01-13 Astrazeneca Ab Quetiapine metabolite with antipsychotic activity
AU2004253334A1 (en) 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
EP1689367A1 (en) 2003-10-21 2006-08-16 Actavis Group HF Pharmaceutical formulations containing quetiapine
US20050171088A1 (en) 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2006117675A1 (en) 2005-01-27 2006-11-09 Ocean Nutrition Canada Ltd. Fatty acid-benzenediol derivatives and methods of making and using thereof
EP1898922A4 (en) 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
CA2641718A1 (en) * 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
JP2010507648A (ja) 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸nmda活性を有する新規向精神薬
EP2120563A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USES
EP2519101B1 (en) 2009-12-31 2015-08-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same

Also Published As

Publication number Publication date
EP2544536A4 (en) 2013-08-14
US20150044261A1 (en) 2015-02-12
EP2544536B1 (en) 2018-12-12
US9511149B2 (en) 2016-12-06
US8900604B2 (en) 2014-12-02
US20130045247A1 (en) 2013-02-21
PT2544536T (pt) 2019-01-23
TR201900067T4 (tr) 2019-02-21
HUE042945T2 (hu) 2019-07-29
WO2011112657A1 (en) 2011-09-15
EP3476218A1 (en) 2019-05-01
RS58335B1 (sr) 2019-03-29
US20130158007A1 (en) 2013-06-20
US20170246301A1 (en) 2017-08-31
SMT201900079T1 (it) 2019-02-28
PL2544536T3 (pl) 2019-05-31
US20170042906A1 (en) 2017-02-16
US9890150B2 (en) 2018-02-13
US9889198B2 (en) 2018-02-13
LT2544536T (lt) 2019-02-25
DK2544536T3 (en) 2019-02-04
SI2544536T1 (sl) 2019-03-29
EP2544536A1 (en) 2013-01-16
US20170247368A1 (en) 2017-08-31
CY1121106T1 (el) 2019-12-11
ES2705233T3 (es) 2019-03-22
US20110223207A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
HRP20190057T1 (hr) Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih
IL269322B (en) Methylphenidate-medications, processes for their preparation and use
PL3564361T3 (pl) Organoid wątroby, jego zastosowanie i sposoby hodowlane jego otrzymywania
SG11201406511VA (en) Catalysts for the production of acrylic acid or its derivatives
SG11201503646TA (en) Esterification of 2,5-furan-dicarboxylic acid
LT2895653T (lt) Tirpios celiuliozės gamybos būdas, tirpi celiuliozė ir būdo panaudojimas
IT1405680B1 (it) Processo per la produzione di l-fucosio.
BR112013002124A2 (pt) células e processo para a produção de ramnolipídeos
BR112014022814A2 (pt) catalisador ácido sólido, método de produção do mesmo e método de produção de alquil éster de ácido graxo utilizando o mesmo
PL2843039T3 (pl) Nowy szczep produkujący kwas D-mlekowy i jego zastosowanie
PL2865038T3 (pl) Elektroda dwubiegunowa i sposób jej wytwarzania
HUE049168T2 (hu) L-aminosav elõállítására képes mikroorganizmus és eljárás L-aminosav elõállítására annak alkalmazásával
DK2533895T3 (da) Fremgangsmåde til fremstilling af hydrogeneret biodiesel
EP2561040C0 (en) Biofuel production process
EP2813741A4 (en) TIGHTENING COLLAR FOR FLEXIBLE PIPES AND METHOD FOR MANUFACTURING THE NECKLACE
UY33120A (es) Metodo para la producción de ácido metacrílico y acrílico
BR112012025490A2 (pt) ''método para produção de 1,5 oebtanodiamina''
FR2959991B1 (fr) Procede de preparation de fluorosulfates de metal alcalin et de metal de transition
PL2588232T3 (pl) Materiał katalityczny i sposób jego wytwarzania
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
EP2939672A4 (en) PROMOTER OF IGF-1 PRODUCTION
BR112013012565A2 (pt) composições e métodos para produção de enteroquinase em levedura
EP2546351A4 (en) PROCESS FOR MAKING SUCCINIC ACID
DK2591119T4 (da) Fermenteringsproces
BR112013012053A2 (pt) processo e dispositivo para produção de ácido glucônico